AU2016252885B2 — Compositions and methods for treating mycobacteria infections and lung disease
Assigned to Matinas Biopharma Nanotechnologies Inc · Expires 2021-05-20 · 5y expired
What this patent protects
Disclosed are methods of treating mycobacteria infections, such as nontuberculosis mycobacterial (NTM) lung disease and pulmonary tuberculosis, including refractory lung disease, by orally administering encochleated antibiotics, including aminoglycosides, such as amikacin. Orally…
USPTO Abstract
Disclosed are methods of treating mycobacteria infections, such as nontuberculosis mycobacterial (NTM) lung disease and pulmonary tuberculosis, including refractory lung disease, by orally administering encochleated antibiotics, including aminoglycosides, such as amikacin. Orally administered antibiotic cochleates have significantly reduced toxicity as compared to intravenously administered antibiotics.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.